Showing 6251-6260 of 7326 results for "".
- Aclaris to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meetinghttps://practicaldermatology.com/news/aclaris-to-support-symposium-on-jak-inhibitors-at-the-international-investigative-dermatology-2018-meeting/2457767/Aclaris Therapeutics, Inc. has provided an unrestricted educational grant for the symposium on Janus Kinase (JAK) inhibitors at the International Investigative Dermatology (IID) 2018 Meeting in Orlando, FL. The symposium, titled “JAKs Be Nimble: New Applications of JAK Inhibitors in Dermato
- And the Winner Is...Consumer Reports Releases Annual Sunscreen Ratingshttps://practicaldermatology.com/news/consumer-reports-releases-annual-sunscreen-ratings/2457769/Drumroll please… The annual Consumer Reports sunscreen ratings are in. Just one product, La Roche-Posay Anthelios 60 Melt-In Sunscreen Milk, came
- Sinclair Will Market and Distribute Silhouette InstaLift in UShttps://practicaldermatology.com/news/sinclair-to-market-and-distribute-silhouette-instalift-in-the-us/2457773/Silhouette Lift, Inc.. a Sinclair Pharma Company, is now handling all of the commercial aspects of the Silhouette InstaLift portfolio of resorbable skin lifting sutures including sales and marketing, and order fulfillment. They are also relaunching
- Sciton Announces New Leadership Teamhttps://practicaldermatology.com/news/sciton-announces-new-leadership-team/2457777/Sciton has an all new leadership team. The new Sciton leaders are: Aaron Burton, Chief Operating Officer Todd Sternbach, Vice President of Strategic Sales Initiatives David Percival, Vice President / General Manager of Sciton International Lacee Jacobson Na
- SENTÉ Launches Illuminé Eye Creamhttps://practicaldermatology.com/news/sent-launches-illumin-eye-cream/2457774/SENTÉ® Illuminé Eye Cream to help diminish the appearance of redness and periorbital discoloration is now available. The formulation also improves the appearance of wrinkles and crepiness, as well as the appearance of puffiness, the company says.
- Innovations in Skin of Color Dermatology Award Goes to Eliot Battle, MDhttps://practicaldermatology.com/news/innovations-in-skin-of-color-dermatology-award-goes-to-eliot-battle-md/2457775/Eliot Battle, MD has been awarded the Innovations in Skin of Color Dermatology Award. The award was presented by The&nbs
- DermTech Partners with Melanoma Research Foundation to Support Miles for Melanomahttps://practicaldermatology.com/news/dermtech-partners-with-melanoma-research-foundation-to-support-miles-for-melanoma/2457781/DermTech, Inc. is partnering with the Melanoma Research Foundation in support of five Miles for Melanoma Runs/Walks held throughout the US, kicking off this month during Melanoma Awareness
- Sensus Appoints Rita Gable as VP of Sales, Oncologyhttps://practicaldermatology.com/news/sensus-appoints-rita-gable-as-vp-of-sales-oncology/2457783/Sensus Healthcare, Inc. has appointed Rita Gable as Vice President of Sales – Oncology. Ms. Gable, who will report to Joe Sardano, Sensus CEO, has 15 years of sales e
- FDA Approves Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600-Mutant Melanomahttps://practicaldermatology.com/news/fda-approves-tafinlar-mekinist-for-adjuvant-treatment-of-braf-v600-mutant-melanoma/2457786/The FDA has approved Novartis' Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. The FDA
- FDA Agrees to Priority Review of Cemiplimab for Advanced Squamous Cell Carcinomahttps://practicaldermatology.com/news/fda-agrees-to-priority-review-of-cemiplimab-for-advanced-squamous-cell-carcinoma/2457785/The FDA has accepted the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC w